Kornimate/medical-research-clean huggingface dataset:
intralesional injections of triamcinolone for acne vulgaris

Conditions: Acne Vulgaris

Summary: this proof-of-concept study seeks to investigate the safety of intralesional injections of triamcinolone for acne vulgaris lesions using an intradermal needle adapter.

this is an open-label, prospective, single-arm study. approximately 20 subjects will be enrolled at 1 study site. all subjects will receive treatment with the study protocol (i.e., intralesional injection with triamcinolone) at visit 1 (day 1). subjects will then attend in-clinic visits at visit 2 (24-hours post-injection), visit 3 (48-hours post-injection), visit 4 (72-hours post-injection), visit 5 (day 7), and visit 6 (day 14). efficacy assessments (target lesion assessments, photography) and safety assessments will be conducted by the investigator at each study visit. subjects will conduct lesion pain assessments at each study visit as well as satisfaction assessments at each post-treatment visit.

Eligibility criteria:
inclusion criteria: * outpatient, male or female of any race, 18 years of age or older. female subjects of childbearing potential must have a negative urine pregnancy test at baseline. * diagnosed with facial acne vulgaris. * at least one (1) identifiable inflammatory lesion that, in the opinion of the investigator, is amenable to intralesional injection of triamcinolone. * able to follow study instructions and likely to complete all required visits. * in good general health as determined by medical history at the time of screening (investigator discretion). * sign the irb-approved informed consent form (including hipaa authorization) prior to any study-related procedures being performed exclusion criteria: * female subjects who are pregnant or breast-feeding. * known hypersensitivity or previous allergic reaction to any constituent of triamcinolone injection. * active cutaneous viral infection in any treatment area at baseline. * have concomitant skin disease or infection (other than acne) or presence of skin comorbidities in the areas of skin where study device will be used. * history of poor cooperation or unreliability (investigator discretion). * planning to move out of the area prior to study completion. * subjects who are investigational site staff members or family members of such employees. * exposure to any other investigational /device within 30 days prior to visit 1.
effect of occupational therapy on the function and mobility of elbow fractures

Conditions: Supracondylar Humerus Fracture

Summary: supracondylar humerus fracture are common upper extremity injuries in children accounting for over 400 fractures per year and approximately 25% of all fractures treated at seattle children's emergency department. most of these fractures are treated with splints and casts though more than one-third undergo surgical fixation followed by casting. healing is usually complete after 3-4 weeks, when casts (and pins, if fixed operatively) are removed and motion begun. though stiffness is often a problem after immobilization of adult elbow fractures, stiffness after pediatric elbow fractures is regarded as typically transient. this study addresses the question "does early motion of the arm with physiotherapy promote the return of function and motion in patients with supracondylar humerus fractures?" the investigators will conduct a prospective randomized trial to determine the effect of six occupational therapy visits over a five week period of time on elbow function and mobility after supracondylar humerus fracture. the investigators will measure motion of the elbow and administer the child and parental activity scale for kids performance versions (askp) assessment tool to answer this question.


Eligibility criteria:
inclusion criteria: * have a supracondylar fracture which is isolated, non - comminuted, and less than one week old. * will be treated with either casting or surgery. * lack head injuries or other fractures. * are not cognitively impaired or critically ill. * are 5 - 12 years old * speak english or spanish exclusion criteria: * requires open reduction to align * comminuted or t - intercondylar fracture * other fractures on the same limb * head injury * cognitive impairment * critically ill * mental disorders * fracture occurred more than one week prior to visit.
effect of probiotics on oral homeostasis during sugar stress

Conditions: Dental Caries; Probiotics; Gingivitis

Summary: the present study is a double-blinded randomized clinical trial with a duration of 28 days.

the present study is a double-blinded randomized clinical trial with a duration of 28 days. 80 orally and systemically healthy participant will be allocated in the test (probiotic) and the control (placebo) group at baseline. the intervention is sugar stress, which will be applied at baseline and continue through day 14, followed by 14 days without sugar stress. clinical measurements and sampling will be performed at baseline, day 14 and day 28 primary endpoint: changes in microbial composition. secondary endpoints: changes in clinical and immunological parameters

Eligibility criteria:
inclusion criteria: * age \> 18 yrs. exclusion criteria: * presence of oral diseases i.e. gingivitis, periodontitis and dental caries * current smokers * any systemic diseases and current use of any medication with known effect on oral health * use of systemic antibiotics within the latest three months. * age \ 30 yrs.
intraoperative dexmedetomidine infusion in endovascular intervention for aneurysmal subarachnoid hemorrhage

Conditions: Dexmedetomidine; Infusion; Endovascular; Aneurysmal Subarachnoid Hemorrhage

Summary: the aim of this study is to evaluate the role of intraoperative dexmedetomidine infusion in endovascular intervention for aneurysmal subarachnoid hemorrhage.

aneurysmal subarachnoid hemorrhage is a sudden, life-threatening emergency caused by bleeding in the subarachnoid space between the brain and skull. cerebral vasospasm (vsp) is the leading risk factor of neurological deterioration (i.e., delayed cerebral ischemia \[dci\] and cerebral infarction) after aneurysmal subarachnoid hemorrhage (sah) and a cause of morbidity and mortality. dexmedetomidine (dex) is a highly selective α-2 adrenergic receptor agonist. the α -2 receptor agonists have a long track record of use for sedation and analgesia. it has been shown that α -2 agonists are neuroprotective in craniocerebral and subarachnoid injuries. dexmedetomidine has a significant effect on the central nervous system and decreases the blood flow in the brain and the requirement or needs for cerebral oxygen. it also modifies memory and enhances cognitive ability effects like sedation, analgesic, and anxiolytics. dexmedetomidine is shown to decrease catecholamine in the brain and improves the perfusion ability in the penumbra. the glutamate level is significantly reduced by dexmedetomidine (dex), and so injuries at the cellular level is reduced.

Eligibility criteria:
inclusion criteria: * aged \>18 years. * both sexes. * american society of anesthesiologists (asa) i-iii * unruptured subarachnoid hemorrhage (sah) confirmed by digital subtraction catheter angiography (dsa) undergoing endovascular intervention with general anesthesia. exclusion criteria: * subarachnoid hemorrhage (sah) from a lesion other than a ruptured saccular aneurysm. * intraventricular or intracerebral blood in the absence of localized thick or diffuse subarachnoid hemorrhage (sah). * no or localized thin subarachnoid hemorrhage (sah) on computed tomography (ct). * cerebral vasospasm on admission digital subtraction catheter angiography (dsa). * hypotension (systolic blood pressure 90 mm hg) refractory to fluid therapy. * neurogenic pulmonary edema. * cardiac failure requiring inotropic support. * severe or unstable concomitant condition or disease or chronic condition. * kidney and/or liver disease. * prior cerebral damage on computed tomography (ct) scan such as stroke (\>2 cm maximum diameter). * pregnancy. * traumatic brain injury. * previously treated cerebral aneurysm. * arterial venous malformation. * pre-existing cerebrovascular disorder that will affect diagnosis and evaluation of subarachnoid hemorrhage (sah). * ischemic heart disease or second or third-degree atrioventricular block. * long-term abuse of alcohol, opioids, or sedative-hypnotic drugs. * obesity (body mass index \[bmi\] \>30 kg/m2).
the value of orencia in rapidly progressing rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to investigate the value of orencia in rapidly progressing rheumatoid arthritis (ra).


Eligibility criteria:
inclusion criteria: * 18 years of age at enrollment * confirmed diagnosed with ra * initiated first-line treatment with abatacept, adalimumab, etanercept, or infliximab with a record of the start date at the practice site exclusion criteria: * does not have at least 1 or more poor ra prognostic factor: evidence of joint erosions, positive anti-ccp autoantibodies, positive rf autoantibodies, increased crp levels, increased esr levels * was followed at the site for less than 1 year since biologic treatment initiation * patients with autoimmune diseases: crohn's, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis, anal fistula other protocol defined inclusion/exclusion criteria could apply
imaging perilymphatic fistulas after barotrauma

Conditions: Perilymphatic Fistulas

Summary: our objective is to validate the ct / mri combination of non-injected rock for the rapid positive diagnosis of perilymphatic fistulas.


Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 * clinical suspicion of perilymphatic fistula * patient having undergone a rock scan or mri of the middle ear at the strasbourg university hospital with surgical confirmation of the diagnosis (or reversal) exclusion criteria: - refusal of the patient to participate in the study

Keywords: perilymphatic fistulas magnetic resonance imaging (mri) surgery round window vertigo tinnitus cophosis
effects of chair-based exercise training on exercise capacity in patients with acute exacerbation of copd

Conditions: Acute Exacerbation of COPD

Summary: chronic obstructive pulmonary disease (copd) is the leading cause of morbidity and mortality worldwide, a respiratory disease characterized by chronic airflow limitation that is not completely reversible. impaired pulmonary functions, decreased exercise capacity and quality of life and increased dyspnea perception is prevalent in patients with acute exacerbations of copd.it was demonstrated exercise training has beneficial effects in patients with acute exacerbations of copd. the purpose of this study to evaluate the effects of chair-based exercise training on exercise capacity, respiratory functions, dyspnea, balance, depression anxiety and quality of life in copd patients in acute exacerbation.

acute exacerbations of copd are generally defined as events in the natural course of the disease characterized by a change in the patient's initial dyspnea, cough or sputum beyond normal daily variations. the main consequences of copd in acute exacerbation are increased mortality, deterioration in health-related quality of life, faster decline in lung function, marked reduction in physical activity and worsening of peripheral muscle weakness, which have a direct impact on patients' health. although exacerbations are diagnosed based on respiratory symptoms, there is evidence that they have systemic consequences, including a detrimental effect on skeletal muscle function, exercise tolerance and quality of life. chair-based exercise training is defined as a structured and progressive exercise program applied by trainers that provides stability using a chair, which is a part of exercise training for the elderly. it is thought that it would be beneficial to study such an exercise program, since copd patients in acute exacerbation have less mobilization during hospitalization. in a limited number of studies, some inconsistencies were observed in the exercises of patients with acute exacerbation of copd. studies can therefore now focus on investigating comparisons between different intervention lengths, session durations and frequencies, and intensities of exercise training. for this reason, in our planned study, we will investigate the effects of chair-based exercise training in copd patients in acute exacerbation. there is no study in the literature investigating the effects of chair-based exercise training in copd patients in acute exacerbation. for this reason, our study will provide important information support to the literature.

Eligibility criteria:
inclusion criteria: * patients who were hospitalized due to acute exacerbation of copd exclusion criteria: * patients with orthopedic or neurological problems that may interfere with assessment and education, * uncooperative patients, * patients with advanced heart problems such as acute coronary syndrome, stable angina pectoris, severe arrhythmias (atrial fibrillation etc.), decompensated heart failure.

Keywords: chair-based exercise training
characterization of the use of antipsychotics in ptsd during the past seven years

Conditions: PTSD; Post-Traumatic Stress Disorder

Summary: the primary objective is to examine the percentage of patients with ptsd who were prescribed an antipsychotic over the past seven years in the va network 7 (al, ga, sc) and compare the percentage on an annual basis. we will also determine the type and dose of antipsychotics received. we hypothesize that there has been a significant increase in antipsychotic use, especially atypical antipsychotics, prescribed for patients with ptsd over the last 7 years

this study is a retrospective electronic review of the visn 7 data warehouse to determine what have been the emerging trends in prescriptions of atypical antipsychotic medications over the past seven years for the treatment of posttraumatic stress disorder (ptsd) in the va this study is a retrospective electronic review of patients of the visn 7 data warehouse of patients with a diagnosis of ptsd treated with antipsychotics as monotherapy or adjunctive therapy at a va medical center or va clinic in visn 7 (ga, sc, and al). the data will be retrieved from a computerized list of patients treated in va visn 7 for ptsd from 1998-2005 and cross-referenced with the electronic pharmacy file for having received a prescription of an antipsychotic medication. no personal identifiers will be collected. the data will then be examined to determine what type of antipsychotics were prescribed and the dose and duration of the antipsychotics. in addition, demographics and clinical characteristics available through the data warehouse will be collected.

Eligibility criteria:
inclusion criteria: * male or female patients, any race or ethnic origin at least 19 years of age. * patients with a diagnosis of ptsd * treated with an antipsychotic as a monotherapy or adjunctive therapy * patient must have been seen at a va medical center or clinic within visn 7 during the study period. exclusion criteria: * patients not diagnosed with ptsd * not treated with an antipsychotic as a monotherapy or adjunctive therapy * patients outside of network 7 * patients with a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder

Keywords: antipsychotics ptsd post traumatic stress disorder monotherapy adjunct therapy
hypoglycemia and autonomic nervous system function

Conditions: Hypoglycemia

Summary: the goals of this proposal are to determine the effects of hypoglycemia on the autonomic nervous system.


Eligibility criteria:
inclusion criteria * healthy volunteers * males and females age 18 to 50 years exclusion criteria * pregnancy * lactation * subjects who smoke or are on other forms of nicotine will be excluded * clinically evident coronary artery, cerebrovascular, or peripheral vascular disease, or presence of systemic illness that might affect autonomic function. such illnesses include diabetes mellitus, congestive heart failure, hypertension, renal, pulmonary, hepatic disease, anemia, malignancies, untreated thyroid disease, and alcoholism. * current major depressive illness * any individuals on oral, injected, inhaled or topical corticosteroids within the last year or oral contraceptives within the past 3 months will be excluded. * use of medications other than thyroxine

Keywords: hypoglycemia autonomic nervous system baroreflex sensitivity muscle sympathetic nerve activity lower body negative pressure
recovery from dnmb using different sugammadex doses in elderly patients undergoing robot-assisted prostatectomy

Conditions: Prostate Cancer; Neuromuscular Blockade

Summary: the aim of this prospecive randomized study is to evaluate the effects of a dose of sugammadex increased by 50% compared to a standard dose on recovery time from deep neuromuscular block in elderly patients undergoing robot-assisted laparoscopic radical prostatectomy (ralp). secondary objectives are to evaluate the different extubation time, time to exit from the operating room (or), lenght of stay in post-anaesthesia care unit (pacu) and safety (hemodynamic parameters and respiratory function).

an increasing percentage of elderly patients with localized prostate cancer undergo ralp, due to the higher safety and feasibility of this minimally invasive surgical option compared to standard open procedure. this procedure is performed under deep neuromuscular block (dnmb) in order to guarantee an adequate working space. induction and maintenance of the dnmb require neuromuscular monitoring and adequate reversal at the end of the intervention to prevent postoperative residual curarization (porc). sugammadex is the most attractive strategy to titrate reversal according to nmb monitoring data and to ensure a complete recovery of muscle function before extubation. in elderly patients, the risk of porc and related postoperative complications is higher. for these reasons, we hypothesize that a dose of sugammadex increased by 50% compared to a standard dose could significantly shorten neuromuscular recovery time, extubation time, or discharge time and pacu length of stay in elderly patients undergoing ralp.

Eligibility criteria:
inclusion criteria: * patient's age ≥65years * prostate cancer * robot-assisted laparoscopic radical prostatectomy (ralp) exclusion criteria: * inability to obtain written informed consent * history of significant liver, renal or pulmonary diseases * current smoking * chronic or acute alcoholism * known or suspected neuromuscular disorders * family history of malignant hyperthermia * any pre-existing coagulopathy * abnormal blood coagulation tests (including prothrombin time \ 38 seconds and inr \>1.20) or preoperative anticoagulant therapies * bmi ≥30 kg/m2 * known allergy or hypersensitivity to the drugs used in the study * planned postoperative admission to intensive care unit. * moderate neuromuscular block (tof 1-3) at the end of surgery

Keywords: sugammadex elderly recovery time robotic surgery
prevention of hand eczema among workers in the fishing industry in greenland

Conditions: Hand Eczema

Summary: this study aims to investigate the effect of a prevention programme on hand eczema among workers in the greenlandic fishing industry. this is a non-randomised clinical trial including employees at approximately three of royal greenland's fish processing facilities in greenland.


Eligibility criteria:
inclusion criteria: * employee in royal greenland, a state-owned company and one of the largest seafood enterprises in the world * written informed consent exclusion criteria: * age below 18 years * inability to understand the greenlandic, danish or english language * pregnancy * other chronic skin diseases on the hands * receiving immunomodulatory therapies
a study evaluating the efficacy of venetoclax plus ibrutinib in participants with t-cell prolymphocytic leukemia

Conditions: Leukemia; T-cell Prolymphocytic Leukemia (T-PLL); Cancer

Summary: the main objective of this study is to evaluate the efficacy of the combination of venetoclax plus ibrutinib for treating adults with t-cell prolymphocytic leukemia (t-pll).

this study is planned as an adaptive 2-stage design as follows: stage 1: enroll 14 participants with relapsed or refractory (r/r) t-pll and move to stage 2 if 4 or more participants meet protocol-specified response criteria. response assessment will be performed on a continued basis until all 14 participants have enrolled into stage 1 and have completed the week 24 disease assessment. stage 2: enroll up to an additional 23 participants. the study was stopped after stage 1. stage 2 was not conducted.

Eligibility criteria:
inclusion criteria: * adequate liver, kidney and hematology function per laboratory values as described in the protocol. * diagnosis of t-cell prolymphocytic leukemia (t-pll) that requires treatment. * eastern cooperative oncology group (ecog) performance status less than or equal to 2. * received prior alemtuzumab (unless unsuitable or unavailable). * has no malignancies other than t-pll that: * currently require systemic therapies; * were not previously treated with curative intention (unless the malignant disease is in a stable remission due to the discretion of the treating physician); or * developed signs of progression after curative treatment. exclusion criteria: * history of or current decompensated cirrhosis including child-pugh class b or c, ascites, hepatic encephalopathy, or variceal bleeding. * has human t-cell lymphotropic virus, type 1. * prior allogeneic stem cell transplant within 6 months of study drug administration and requirement for graft versus host therapy. * has an uncontrolled or active infection including severe acute respiratory syndrome- coronavirus-2 (sars-cov-2). * previously treated with a b-cell lymphoma (bcl)-2 inhibitor. * received a prohibited therapy within the specified time frame as described in the protocol.

Keywords: t-cell prolymphocytic leukemia (t-pll) cancer venetoclax venclexta venclyxto ibrutinib imbruvica relapsed or refractory t-lymphoid malignancy
erector spine plane (esp) block for analgesia in pediatric scoliosis surgery

Conditions: Scoliosis; Regional Anesthesia; Pediatric Anesthesia; Orthopedic Disorder of Spine

Summary: postoperative pain after scoliosis correction surgery is severe and usually requires long-term intravenous opioid therapy. local anesthetic options are limited and include intrathecal opioids and epidural analgesia. however, they are rarely used due to side effects and inconsistent efficacy. the investigators describe an opioid-sparing multimodal analgesia regimen with bilateral erector spinae plane blocks.

posterior spinal fusion for scoliosis correction is extremely painful and usually requires long-term, high-dose opioid use for adequate perioperative analgesia. neuromonitoring, i.e., motor-evoked and somatosensory-evoked potentials (sseps), are the current gold standard for preventing neurological damage. local anesthesia is essential to multimodal analgesia, but options are limited. intrathecal or epidural opioid injections of local anesthetics have been reported but are rarely used due to logistical complexity, side effects, and inconsistent analgesic efficacy. the erector spinae plane (esp) block was first described in 2016 for thoracic neuropathic pain. it is a new interfacial plane technique. easy to perform on patients without spinal deformities. it was successfully used for surgery in adults. however, even with ultrasound guidance, identifying bone markers in scoliosis patients is challenging. the investigators will treat patients for scoliosis with single-shot bilateral esp blocks. the investigators aim to provide effective perioperative pain control and achieve intraoperative hemodynamic stability without compromising neuromonitoring.

Eligibility criteria:
inclusion criteria: * patients \< 18 years old undergoing scoliosis surgery exclusion criteria: * refusal to participate * \> 18 yo * chronic opioid use * localized infection

Keywords: erector spine plane block neuromonitoring pain management multimodal analgesia